« Return to News | Clinical Intelligence

BioAlliance Pharma initiates phase II trial of Validive

Tuesday, June 11, 2013 04:04 PM

BioAlliance Pharma, a developer of orphan oncology products and supportive care products, initiated its phase II clinical trial evaluating the efficacy and safety of Validive (clonidine Lauriad) in the U.S. in patients with chemoradiation therapy-induced oral mucositis with head and neck cancer.

The first U.S. investigational sites were initiated in May and are ready to start recruiting patients, while a total of 20 U.S. sites are planned to be initiated in the coming weeks.

The clinical trial is being conducted in 30 centers in four countries: France, Germany, Spain and Hungary.

More than 60% of planned patients have been enrolled in Europe and the U.S. extension is planned to help accelerate the recruitment. The trial is expected to be finalized in late 2013 to early 2014 with results in 2014.

Severe oral mucositis occurs in more than 60% of patients treated with radio/chemotherapy for head and neck cancer, and currently has no validated curative or preventive treatment. It may induce intense oral pain and eating disability leading to hospitalization and enteral or parenteral nutritional support. The disease also frequently requires stopping, sometimes for a prolonged period, the cancer treatment protocol, thus strongly impacting treatment efficacy for the patient.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.